Reports Q4 revenue $8.3M, consensus $7.95M. “We took a giant step forward in diabetes care in 2024, delivering on our promise of One Year, One CGM, with the Eversense 365 CGM system. The feedback we have received from patients and providers has been very positive, and we are just getting started. We see our 365 day product as the catalyst for revenue growth, as well as for the future of blood glucose monitoring,” said Tim Goodnow, president and CEO of Senseonics (SENS). “Eversense 365 is the foundational base for the next generation Gemini and Freedom systems, and we are progressing in our plans to add automated insulin delivery with pump connectivity to Eversense 365.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SENS:
- Senseonics options imply 8.2% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, March 03, 2025
- Options Volatility and Implied Earnings Moves This Week, March 03 – March 06, 2025
- SENS Upcoming Earnings Report: What to Expect?
- Senseonics Holdings: Strong Market Position and Growth Potential with Eversense 365 Launch and Strategic Collaborations